Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience

E D Pouwels, D J Blom, J C Firth, H E Henderson, A D Marais

Lipoprotein lipase deficiency causes severe hypertriglyceridaemia due to chylomicronaemia, and leads to recurrent and potentially life-threatening pancreatitis. This disorder can only be managed by dietary fat restriction as drugs are ineffective.

We review the experience with familial chylomicronaemia in patients who attended the lipid clinics at Groote Schuur Hospital and Red Cross Children’s War Memorial Hospital in Cape Town. Criteria for inclusion were an initial plasma triglyceride concentration of >15 mmol/l and a typical type I Fredrickson hyperlipidaemia pattern on plasma lipoprotein electrophoresis. A total of 29 patients were seen over 25 years. The mean age of presentation was 10 years, but ranged from 0 to 43 years. The modes of presentation differed: pancreatitis (N=16), eruptive xanthomata (N=2), coincidental detection of hypertriglyceridaemia (N=2), screening relatives (N=7), and after death from pancreatitis (N=1). Plasma triglycerides responded rapidly and dramatically to dietary fat restriction, and some patients sustained good control of the hyperlipidaemia. The onset of pancreatitis was earlier in patients of Indian ancestry, suggesting a genotype/phenotype interaction within this disorder. Genetic work-up indicated founder effects in the Afrikaner and Indian patients.

Lipaemic plasma should be taken seriously at all ages, and necessitates work-up at specialised clinics where the diagnosis of chylomicronaemia or type I hyperlipidaemia facilitates appropriate dietary management that can prevent pancreatitis.


Severe hypertriglyceridaemia (>15 mmol/l) is often encountered in clinical practice, where it is usually secondary to diabetes, alcohol excess, renal disease or medication. Familial chylomicronaemia (Fredrickson type I hyperlipoproteinaemia) is a rare cause of severe hypertriglyceridaemia. This autosomal recessive disorder affects about one in a million persons and is caused by defective plasma lipoprotein lipase (LPL) activity.1-3 Rarely, familial chylomicronaemia is due to a complete (homozygous) deficiency of apolipoprotein C-II,7 which is the co-factor for LPL. A few cases of chylomicronaemia are caused by auto-antibodies to LPL.4

LPL is active at the capillary endothelium where it is bound to cell surface proteoglycans, from which it may be released by heparin.1 The primary function of LPL is the hydrolysis of triglycerides of very-low-density lipoproteins (VLDLs) and chylomicrons (CM), thereby delivering free fatty acids to muscle and adipose tissue for energy production or storage.6,7 After ingestion and lipolysis of dietary triglyceride in the gut, there is complete absorption of non-esterified fatty acids into the enterocyte. The dietary fat is re-assembled into triglyceride, incorporated into CMs and released into the systemic circulation. These large particles scatter light, imparting opalescence in plasma from normal subjects in the postprandial state. The importance of LPL can be inferred from the systemic circulation. These large particles scatter light, imparting opalescence in plasma from normal subjects in the postprandial state. The importance of LPL can be inferred from the limited postprandial rise of plasma triglyceride from a typical diet that contains about 100 mmol of triglyceride per day. The absence of LPL results in very retarded CM clearance evident as lipaemia.1 LPL-deficient patients, can be lethal. On physical examination, some patients sustained good control of the hyperlipidaemia. The onset of pancreatitis was earlier in patients of Indian ancestry, suggesting a genotype/phenotype interaction within this disorder. Genetic work-up indicated founder effects in the Afrikaner and Indian patients.

About 25% of patients with familial chylomicronaemia manifest complications before the age of 1 year, and the majority develop complications before the age of 10 years.3,10 Some patients present for the first time during pregnancy.10,11 Symptoms include severe abdominal pain, repetitive colicky pain or failure to thrive. Acute pancreatitis, often recurrent in LPL-deficient patients, can be lethal. On physical examination, eruptive xanthomata are frequently present (Fig. 1) and lipaemia retinalis can be observed.2 Although the clinical presentation is nonspecific, especially at a younger age,2 the plasma of the patients is always lipaemic.
Our aim is to make South African medical practitioners aware of this rare, but simply treatable, disorder which has been found in several ethnic groups.

**Methods**

The records were reviewed of all patients with familial chylomicronaemia who attended the lipid clinics of Groote Schuur and/or Red Cross War Memorial Children’s hospitals in Cape Town between 1984 and 2006. The inclusion criteria were: initial plasma triglyceride concentration >15 mmol/l and the demonstration of practically only CM on electrophoresis (Fredrickson type I hyperlipidaemia).

Plasma lipid and lipoprotein concentrations were measured employing conventional automated spectrophotometric assays. In the majority of cases, genetic analysis of the LPL gene was also undertaken (and has been reported with international collaboration) that also determined LPL activity in a few cases.

**Results**

There were 29 patients from 21 kindreds. Ten of the subjects were Indian, 9 were coloured, 8 were of Afrikaner extraction, and 2 were black (1 Xhosa and 1 Zulu). Twenty-seven patients were from the Western Cape Province, 1 from KwaZulu-Natal, and 1 from Mauritius.

Ages at presentation varied from 2 weeks to 43 years, with a mean age of 10 years. Sixteen patients attended the clinic for the first time because of an attack of pancreatitis, 2 children presented with eruptive xanthomata, 1 male infant was diagnosed after death, 1 woman had incidentally discovered hypertriglyceridaemia, 1 boy was diagnosed following a stroke that was attributed to hypertriglyceridaemia, and 8 patients were diagnosed by family screening.

Nine of the 29 patients had undergone abdominal surgery: appendectomy and/or cholecystectomy. One patient had a modified Whipple’s procedure owing to intractable pain from recurrent pancreatitis. He was treated for exocrine pancreatic insufficiency and later became diabetic. Seven of the patients had diabetes, probably secondary to the repetitive attacks of pancreatitis. The 5 patients with hypertension may reflect the high prevalence of this disorder but may also suggest a relationship with hypertriglyceridaemia and/or diabetes.

All patients displayed a marked decrease in plasma triglycerides after dietary treatment. The mean worst triglyceride of 56±41 mmol/l fell to 10.9±8.8 mmol/l. No significant differences in triglyceride concentrations were seen between genders before and after treatment. Follow-up data are incomplete because patients with good dietary adherence generally obviate pancreatitis and remain well. Patients who adhered to diets restricting triglyceride to <10 g/d for short periods achieved fasting triglyceride concentrations of <6 mmol/l. Five of the 10 women were pregnant. Four had much increased plasma triglyceride concentrations despite meticulous diets, but fortunately escaped complications. The fifth patient had 21 hospital admissions for pancreatitis during her pregnancy, compared with 4 attacks before pregnancy and none in the 8 years thereafter. In this patient, life-threatening pancreatitis necessitated urgent caesarean section with a good outcome at 32 weeks' gestation.

Four different LPL gene mutations were detected in this cohort of patients, with some segregation of mutations with ethnic groupings: 7 of the 8 Afrikaner patients (6 kindreds) were homozygous for the I194T mutation, while all 9 of the Indian patients (4 kindreds) were homozygous for the Q188R mutation (Table I).

---

**Table I. Lipoprotein lipase mutations identified in various ethnic groups at the lipid clinics of Groote Schuur Hospital and Red Cross War Memorial Children’s Hospital**

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Afrikaner</th>
<th>Mixed ancestry</th>
<th>Indian</th>
<th>Black</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q188R</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>I194T</td>
<td>7</td>
<td>2*</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C418Y</td>
<td>0</td>
<td>1*</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>E421K†</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>102/Ins GGGCT</td>
<td>0</td>
<td>5</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Unknown</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* One patient was a compound heterozygote for the I194T and C418Y mutations.
† Found in heterozygous form in patient who died from pancreatitis in pregnancy.
Phenotype/genotype relationships have not been characterised well in LPL deficiency. In our patient cohort, the I194T mutation was associated with a delayed presentation of pancreatitis when compared with the Q188R mutation. Of the 7 patients homozygous for the I194T mutation, 3 never had a history suggestive of pancreatitis, while 3 had their first attack after the age of 20 years, and only 1 of the 7 had an attack at a young age (3 months). In contrast, all the patients homozygous for the Q188R mutation were of Indian extraction and had their first attack of pancreatitis before or at the age of 10 years. They had higher untreated plasma lipids as well as more frequent and more severe attacks compared with subjects with the I194T mutation. While there may be differences in lipoprotein metabolism according to the nature of the LPL mutation, diet might also have had an influence. A detailed analysis in 3 Afrikaners indicated a higher fat intake than in 3 Indian patients, suggesting that other factors also play a role in the pathogenesis of pancreatitis. The coloured patients varied widely according to their age of presentation, age of first pancreatitis attack and lipid values. A brother and sister presumed to have Malayan ancestry had an insertion in exon 3 (del 102; insertion GGGCT). The mutation(s) in the two black patients had not yet been determined.

**Discussion**

LPL deficiency causes massive accumulation of chylomicrons in plasma. The clinical presentation is heterogeneous and nonspecific, but the risk of pancreatitis is high and is remediable by dietary fat restriction. Our study documents one of the largest series of patients with familial chylomicronaemia managed at a single centre. The lipid clinic experience at Groote Schuur and Red Cross War Memorial Children’s Hospitals indicates that familial hyperchylomicronaemia is present in multiple ethnic groups and responds to diet. Additionally, there are founder effects in the Afrikaner and Indian populations. There may also be differences in the occurrence of pancreatitis in different genotypes or population groups.

Some additional comments can be made from our experience. Since one child died at 2 months of age and another required ventilation at the age of 3 months as a result of poor labelling of foods. Children may unwittingly consume fatty foods or may be poorly adherent when rebellious during adolescence. Additional management includes avoiding agents known to increase endogenous triglyceride, such as alcohol, oestrogens and retinoic acid derivatives. Diuretics and beta-adrenergic blocking agents have a lesser impact and may be used judiciously. The lipid-lowering drugs are not effective in familial LPL deficiency, as they do not correct the defective enzyme function. LPL is not replaced by a functional protein when fibrates are used, even though LPL is upregulated through the PPARα system. Orlistat causes malabsorption of dietary fat through inhibiting pancreatic lipase but is not a practicable agent as it causes steatorrhoea in doses required to make a meaningful difference. Gene therapy is awaited but may have limited duration of efficacy and may elicit an immune response to LPL that may appear foreign to the patient’s immune system.

There appears to be an increasing risk of pancreatitis according to plasma triglyceride concentrations, but high concentrations may sometimes be tolerated for weeks. Subclinical pancreatitis may cause significant harm to the pancreas and could lead to exocrine and/or endocrine insufficiency. The exact pathogenesis of pancreatitis is unclear. It is believed that the high CM concentration in the pancreatic microcirculation may impair oxygen delivery to the parenchymal cells that house enzymes able to digest biological tissue. Traces of pancreatic lipase may produce unesterified fatty acids, damaging endothelial cells and promoting thrombosis and infarction. Free radical damage to cells may perpetuate damage. Once significant tissue damage
has occurred, the process allows pancreatic enzymes to gain access to the systemic circulation so that the lungs and kidneys may also be injured. Fatty acids may bind calcium to cause hypocalcaemia.

In severe hypertriglyceridaemia, the diagnosis of pancreatitis by plasma enzyme activities often cannot be confirmed by spectrophotometric assays since high triglyceride concentrations interfere with laboratory tests. Other laboratory investigations can also be disturbed as a result of increased triglyceride levels, such as sodium, haemoglobin and bilirubin (artificially low). Accumulation of triglycerides in reticuloendothelial cells can lead to hepatomegaly, splenomegaly, and -- rarely -- also lymphadenopathy.

The best phenotypic test for chylomicronaemia is agarose gel electrophoresis. Chylomicronaemia may also be due to apoC-II deficiency that is also recessively inherited but may be clinically less severe than LPL deficiency and could respond to fresh plasma infusion. Definitive lipase assays are expensive, and are therefore not routinely available, but can discriminate between LPL deficiency, apoC-II deficiency and inhibitors for LPL. Secondary chylomicronaemia due to the inhibition of LPL by an antibody has also been seen in our clinic. LPL is a member of a family of lipases with catalytic activity in a serine protease-like hydrophobic pocket, including pancreatic lipase, hepatic lipase and endothelial lipase. About 100 different mutations have been identified in the human LPL gene, of which 20% occur in the non-coding regions and 80% in the coding regions. Most of the molecular defects are clustered in exon 5 (48.4%) and exon 6 (26.2%), spanning the catalytic pocket to account for about 75% of all mutations. Some mutations result in only moderate effect on LPL activity.

Unusual and severe problems such as LPL deficiency are best managed at specialised tertiary centres that ought to serve patients from the public and private health care sectors. In the public health care sector, several patients have been admitted repeatedly for management of ‘acute abdomen’ before the aetiological diagnosis was made, but lipid-modifying medication was not prescribed as a result of supply restrictions of lipid-modifying drugs to lipid clinics. In the private health care sector, unnecessary admissions also occurred but, despite review of prescriptions, inappropriate medication was prescribed: simvastatin, atorvastatin and bezafibrate. Inappropriate attention was given to the hypercholesterolaemia, and the disproportionate rise in triglyceride concentration was not recognised as the clue to elevated chylomicron concentration.

Evidence is emerging that chylomicronaemia may be atherogenic. The complication of diabetes mellitus with a resultant hepatic overproduction of very-low-density lipoprotein from the liver induces a Fredrickson type V hyperlipidaemia that may also contribute to atherosclerosis.

The authors thank the Chief Medical Superintendent for permission to publish, and also acknowledge the assistance of lipid clinic and laboratory staff.

References